188 related articles for article (PubMed ID: 29900015)
21. Relationship of HIF‑1α expression with apoptosis and cell cycle in bone marrow mesenchymal stem cells from patients with myelodysplastic syndrome.
Qu B; Han X; Zhao L; Zhang F; Gao Q
Mol Med Rep; 2022 Jul; 26(1):. PubMed ID: 35642674
[TBL] [Abstract][Full Text] [Related]
22. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
24. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
25. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
26. [Myelodysplastic syndromes in adults].
Beyne-Rauzy O; Laurent G; Adoue D
Presse Med; 2007 Mar; 36(3 Pt 2):481-91. PubMed ID: 17336857
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndromes.
Zhou J; Orazi A; Czader MB
Semin Diagn Pathol; 2011 Nov; 28(4):258-72. PubMed ID: 22195404
[TBL] [Abstract][Full Text] [Related]
28. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
31. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Microenvironment in MDS: The Final Frontier.
Teodorescu P; Pasca S; Dima D; Tomuleasa C; Ghiaur G
Front Pharmacol; 2020; 11():1044. PubMed ID: 32742264
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplastic syndromes: diagnosis and staging.
Malcovati L; Nimer SD
Cancer Control; 2008 Oct; 15 Suppl():4-13. PubMed ID: 18813205
[TBL] [Abstract][Full Text] [Related]
34. Diagnostics and Prognostication of Myelodysplastic Syndromes.
Zini G
Ann Lab Med; 2017 Nov; 37(6):465-474. PubMed ID: 28840983
[TBL] [Abstract][Full Text] [Related]
35. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow niches in myelodysplastic syndromes.
Tosato G; Feng JX; Ohnuki H; Sim M
J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 34746416
[TBL] [Abstract][Full Text] [Related]
37. I walk the line: how to tell MDS from other bone marrow failure conditions.
Gondek LP; DeZern AE
Curr Hematol Malig Rep; 2014 Dec; 9(4):389-99. PubMed ID: 25079655
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in myelodysplastic syndromes.
Triantafyllidis I; Ciobanu A; Stanca O; Lupu AR
Maedica (Bucur); 2012 Dec; 7(4):295-302. PubMed ID: 23483702
[TBL] [Abstract][Full Text] [Related]
39. The Dawn of next generation DNA sequencing in myelodysplastic syndromes- experience from Pakistan.
Anwar N; Memon FA; Shahid S; Shakeel M; Irfan M; Arshad A; Naz A; Ujjan ID; Shamsi T
BMC Genomics; 2021 Dec; 22(1):903. PubMed ID: 34915860
[TBL] [Abstract][Full Text] [Related]
40. Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes.
Kárai B; Szánthó E; Kappelmayer J; Hevessy Z
EJIFCC; 2013 Jan; 23(4):109-16. PubMed ID: 27683426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
